-
Shanghai Runda Medical Science and Technology Partners with Huawei Cloud on AI in Healthcare
•
China-based Shanghai Runda Medical Science and Technology Co., Ltd (SHA: 603108) is set to collaborate with telecoms giant Huawei Cloud on the construction of a large artificial intelligence (AI) model in the healthcare industry, with the aim of developing and offering smart medical services. Leveraging Expertise for Smart Medical ServicesUnder…
-
Lee’s Pharmaceutical Subsidiary Zhaoke Ophthalmology Announces FDA Review of NVK002 for Pediatric Myopia
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced that the US FDA has accepted for review the New Drug Application (NDA) for Vyluma Inc.’s NVK002, an atropine external use eye solution for pediatric myopia. The FDA has set a Prescription Drug User Fee…
-
Legend Biotech Submits sBLA to Expand Carvykti Label for Relapsed Multiple Myeloma
•
Legend Biotech Corporation (NASDAQ: LEGN) has announced the submission of a supplemental Biologics License Application (sBLA) to the US FDA. The sBLA aims to expand the label for Carvykti (ciltacabtagene autoleucel; cilta-cel) to include the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma who have received at least…
-
Zai Lab and Novocure’s TTFields Show Survival Benefit in NSCLC, Despite Stock Plunge
•
China-based Zai Lab Ltd (ZLAB) (NASDAQ: ZLAB; HKG: 9688) and its partner Novocure Ltd (NASDAQ: NVCR) have presented positive results from the Phase III LUNAR clinical trial at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial evaluated the use of Tumor Treating Fields (TTFields) therapy in…
-
Shanghai Junshi Biosciences to List GDRs on Swiss Exchange, Raising RMB 3.4 Billion
•
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) is preparing to issue 68,292,200 Global Depositary Receipts (GDRs) on the SIX Swiss Exchange. This secondary listing is anticipated to raise a substantial RMB 3.4 billion (USD 480 million), which will be allocated to support research and development (R&D) projects,…
-
CStone Pharmaceuticals Presents Ayvakit Data for Advanced GIST at ASCO 2023
•
China-based CStone Pharmaceuticals (HKG: 2616) announced that new data from a post hoc analysis of the global Phase I NAVIGATOR and Phase I/II China bridging (CS3007-101) studies for Ayvakit (avapritinib) in advanced gastrointestinal stromal tumor (GIST) were presented in a poster discussion session at the 2023 American Society of Clinical…
-
Hansoh Pharmaceutical Gets NMPA Approval for HS-20117 Bispecific Antibody Clinical Study
•
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for HS-20117, a bispecific antibody (BsAb) targeting both EGFR and cMet in advanced solid tumors. Strategic Licensing Deal with BiotheusIn a significant move to expand its…
-
Chinese Pharma Companies Update Pipelines at ASCO 2023 Annual Meeting
•
A number of Chinese pharmaceutical companies have shared updates on their pipeline developments at the 2023 American Society of Clinical Oncology (ASCO) annual meeting. Among them are CSPC Pharmaceutical Group Ltd (HKG: 1093), Alphamab Oncology (HKG: 9966), and Innovent Biologics Inc. (HKG: 1801). CSPC’s CLDN18.2 ADC Demonstrates Promise in Phase…
